This dataset lists the allocations of doses made available for states and jurisdictions to order against. Weekly allocations are provided to states on Tuesdays; after doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week; delivery sites are notified by the private shipping partners. Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020. (Data as of Dec. 22, 2020)
Shipments of an FDA-authorized safe and effective COVID-19 vaccine are arriving at sites across America. Vaccinations began on December 14, 2020. This dataset lists the allocations made available for states and jurisdictions to order against.

Moderna
Doses Allocated for Distribution: 5,990,000
Doses Allocated to Hold for Second Shot: 5,948,600
Safety Stock Allocated: 561,400

Pfizer Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Initial-Allocations-Pfizer/saz5-9hgg

This dataset lists the allocations of doses made available for states and jurisdictions to order against. Weekly allocations are provided to states on Tuesdays; after doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week; delivery sites are notified by the private shipping partners. Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020. (Data as of Dec. 17, 2020)
Shipments of an FDA-authorized safe and effective COVID-19 vaccine are arriving at sites across America. Vaccinations began on December 14, 2020. This dataset lists the allocations made available for states and jurisdictions to order against.

Pfizer
Doses Allocated for Distribution: 2,071,875
Doses Allocated to Hold for Second Shot: 2,071,875
Safety Stock Allocated: 156,250

Weekly Cumulative Estimated Number of Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, 2019-2020 Compared with 2020-2021.

- Since 2019, CDC has been exploring use of data obtained from (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices. These data are being presented publicly for the first time this season; further evaluations of these data are underway.

- The pharmacy data include flu vaccinations that were billed for (i.e. claims) or paid by cash. Medical office data are claims based.

- The sampled pharmacies and physician medical offices and the captured volume of transactions represent approximately 92% and 82% of influenza vaccines administered nationally, respectively.

- Vaccinations administered in other settings such as workplaces and community settings are not included in these data.

- Weekly Number of Influenza Vaccinations Administered, in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, 2019-20 Compared with 2020-21, Data Source(s): IQVIA Pharmacy and Physician Medical Office Claims. Pharmacy Data are current through Week 47 ending Nov 21, 2020. Medical Office Data are current through Week 46 ending Nov 14, 2020

Monthly Cumulative Influenza Vaccination Coverage Among Pregnant Persons, United States, 2019-2020 Compared with 2020-2021.

• These monthly flu vaccination coverage estimates for pregnant persons are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between CDC’s Immunization Safety Office and nine integrated health care organizations. This system has been used annually to estimate vaccination coverage among pregnant persons.

Weekly Cumulative Influenza Vaccination Coverage by Race/Ethnicity, Children aged 6 months through 17 years, United States, 2019-2020 Compared to 2020-2021

- Influenza vaccination coverage among children is assessed through the National Immunization Survey-Flu (NIS-Flu), providing weekly influenza vaccination coverage estimates for children 6 months–17 years. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)

-- NIS-Flu is a national random-digit-dialed cellular telephone survey of households, conducted during the flu season (October-June).

-Additional information on NIS-Flu methods and estimates from 2019-2020 season is available. (https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm)

Weekly Cumulative Influenza Vaccination Coverage, Children 6 months through 17 years, United States, 2019-2020 Compared with 2020-2021
• Influenza vaccination coverage among children is assessed through the National Immunization Survey-Flu (NIS-Flu) annually, providing weekly influenza vaccination coverage estimates for children 6 months–17 years based upon parental report. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)
o NIS-Flu is a national random-digit-dialed cellular telephone survey of households conducted during the flu season (October-June).
• Additional information about NIS-Flu methods and estimates from the 2019-2020 season are available at: https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm.

Weekly Cumulative Influenza Vaccine Doses Distributed in the United States, 2016-2021

• Flu vaccine is produced by private manufacturers. For the 2020-2021 season, manufacturers have projected they will provide as many as 194 to 198 million doses of influenza vaccine for the U.S. market.
• Additional information is available: https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm.

The bipartisan CARES Act and the Paycheck Protection Program and Health Care Enhancement Act provided $175 billion in relief funds to hospitals and other healthcare providers on the front lines of the coronavirus response. The Department of Health and Human Services through the Health Resources and Services Administration is allocating $2 billion in incentive payments to nursing home facilities that reduce both covid-19 infection rates relative to their county and mortality rates against a national benchmark.

A COVID-19 case surveillance restricted access dataset with 31 elements, including state and county of residence information, is available to the public. To access this dataset, complete the Registration Information and Data Use Restrictions Agreement (RIDURA). Other important information is provided below.

Requesting Access

Please review the following documents to determine your interest in accessing the COVID-19 Case Surveillance Restricted Access Detailed Data file:

1) CDC COVID-19 Case Surveillance Restricted Access Detailed Data: Summary, Guidance, and Limitations Information and Restricted Access Data Use Agreement Information

2) Data Dictionary for the COVID-19 Case Surveillance Restricted Access Detailed Data

The next step is to complete the RIDURA. Once complete, CDC will review your agreement. Once access is granted, ASK SRRG (eocevent394@cdc.gov) will email you information about how to access the data through GitHub. If you have questions about obtaining access, email eocevent394@cdc.gov.

Overview

The COVID-19 case surveillance system database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City, the District of Columbia, and U.S. territories. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification. The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC.

COVID-19 case surveillance data are collected by jurisdictions and shared voluntarily with CDC. For more information, visit https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/.

The deidentified data in the restricted access dataset include demographic characteristics (including state and county), exposure history, disease severity indicators and outcomes, clinical data, laboratory diagnostic test results, and comorbidities.

All data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.

The Case Surveillance Task Force and Surveillance Review and Response Group (SRRG), within CDC’s COVID-19 Emergency Response, provides stewardship for datasets that support the public’s access to COVID-19 data while protecting individual privacy.
COVID-19 case reports have been routinely submitted using standardized case reporting forms.

On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19 included. Current versions of these case definitions are available here:

Weekly data on the number of deaths from all causes by sex, age group, and race/Hispanic origin group for the United States. Counts of deaths in more recent weeks can be compared with counts from earlier years (2015-2019) to determine if the number is higher than expected.